A look at MNCs with clinical trials that could be disrupted by the coronavirus outbreak
Almost all major biopharma MNCs are conducting clinical trials in China that could face disruptions as the outbreak of 2019-nCoV acute respiratory disease continues to unfold. An analysis of MNCs most active in the region finds Roche could be hit the hardest.
According to ClinicalTrials.gov, at least 22 MNCs are sponsoring interventional trials in China, and 18 of those companies have trial sites in Wuhan, the epicenter of the viral outbreak. The analysis included studies that are recruiting, enrolling by invitation or active but not recruiting.
Many of these trials could face delays in enrollment, and new trials could see their start dates pushed back, as the Chinese healthcare system scrambles to treat and prevent the spread of the virus (see “China Faces Clinical Delays During Coronavirus Outbreak”).
Some companies are investing more heavily in Chinese trials than others. Roche (SIX:ROG; OTCQX:RHHBY) leads the pack with 63 trials in China, 11 of which have a site in Wuhan.
Trials with sites in China account for one third of Roche’s clinical trials worldwide.
For all other MNCs, trials with sites in China account for less than 10% of their worldwide trials.
Still, several companies are conducting more trials in Wuhan than Roche.
AstraZeneca plc (LSE:AZN; NYSE:AZN) has the most ongoing trials in Wuhan at 21, accounting for almost half of its China trials. AbbVie Inc. (NYSE:ABBV) comes in second with 18 trials in Wuhan.
Though Amgen Inc. (NASDAQ:AMGN) is only running seven trials in China, five are in Wuhan
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus. The 2019nCoV content is free to all who visit the site.
Figure: MNC trials in China
At least 18 biopharma MNCs are conducting clinical trials in Wuhan. BioCentury searched ClinicalTrials.gov for interventional trials sponsored by biopharma MNCs with sites in China. Shown below are the number of trials in Wuhan and elsewhere in China (bars, left axis) and the percentage of each company's worldwide trials with at least one site in China (lines, right axis). Roche includes trials sponsored by Genentech. Bristol-Myers Squibb includes trials sponsored by Celgene. Trials sponsored by multiple companies are counted for each sponsor. Source: ClinicalTrials.gov